Fecha del CVA	01/09/2024

Parte A. DATOS PERSONALES

Nombre *	Pedro José		
Apellidos *	Real Luna		
Sexo *	Hombre	Fecha de Nacimiento *	02/04/1976
DNI/NIE/Pasaporte *	52315325P	Teléfono *	(+34) 958 715500 - 142
URL Web	http://www.genyo.es/content/ver-grupos-de-investigacion?id=12		
Dirección Email	pedroreal@ugr.es		
Identificador científico	Open Researcher and Contributor ID (ORCID) *	0000-0001-7968-5353	
	Researcher ID	K-2994-2014	
	Scopus Author ID		

* Obligatorio

A.1. Situación profesional actual

Puesto	Associate Professor/Principal Investigator		
Fecha inicio	2022		
Organismo / Institución	University of Granada: GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government		
Departamento / Centro			
País		Teléfono	
Palabras clave	240300 - Bioquímica		

A.2. Situación profesional anterior

Periodo	Puesto / Institución / País
2017 - 2022	Principal Investigator (Ramon y Cajal Fellow) / GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government
2013 - 2017	Principal Investigator (Miguel Servet Type I & II Researcher) / GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government
2011 - 2013	Miguel Servet Researcher/ Associate Researcher / GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government
2010 - 2011	Miguel Servet Researcher/ Associate Researcher / Andalusian Stem Cell Bank
2009 - 2010	Sara Borrell Postdoctoral Fellow / Andalusian Stem Cell Bank
2008 - 2009	Sara Borrell Postdoctoral Fellow / Columbia University
2005 - 2009	Postdoctoral Researcher / Columbia University
2005 - 2005	Postdoctoral Researcher / Hospital Universitario Marqués de Valdecilla
1999 - 2005	PhD student / Hospital Universitario Marqués de Valdecilla

A.4. Indicadores generales de calidad de la producción científica

Nr. of Doctoral Thesis: 4
Nr. of Master's Thesis: 18
Nr. of Degree's Thesis: 14
Total citations: 6080*
Last five years citations: 1780*

h-index: 28*
i10-index : 44*
Nr. of publications in Q1: 51/58
Nr. of First author: 9/58
Nr. of First author and corresponding author: 2/58
Nr. of Last author publications: 11/58

*Updated from Google Scholar May 25th 2024

Parte C. MÉRITOS MÁS RELEVANTES

C.1. Publicaciones

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores. Si aplica, indique el número de citaciones

1 **Artículo científico**. Martinez-Navajas G; Ceron-Hernandez J; Simon I; et al; (15/15) Real PJ (AC). 2023. Lentiviral Gene Therapy reverts GPIX expressionand phenotype in Bernard-Soulier Syndrome Type C. Molecular Therapy Nucleic Acids. Elsevier. 33, pp.75-92. https://doi.org/10.1016/j.omtn.2023.06.008

2 **Revisión bibliográfica**. Sanchez Mañas JM; Perez de Gracia N; Perales S; Martinez-Galan J; Torres-Perales C; (6/6) Real PJ (AC). 2024. Clinical implications of Extracellular Vesicles in Pancreatic Cancer: from biomarkers to novel magic bullets (under review). Extracell Vesicles Circ Nucleic Acids. OAE Publishing Inc.. ISSN 2767-6641. https://doi.org/10.5281/zenodo.10553217

3 **Artículo científico**. Domingo-Reines J; Montes R; Garcia-Moreno A; et al; Ramos-Mejia V; (12/14) Real PJ. 2023. Cell Death & Disease. The pediatric leukemia oncoprotein NUP98-KDM5A induces genomic instability that may facilitate malignant transformation.Nature Publishing Group. 14-6, pp.357. https://doi.org/10.1038/s41419-023-05870-5

4 **Artículo científico**. Domingo-Reines J; Martinez-Navajas G; Montes R; et al; Ramos-Mejia V; (11/12) Real PJ. 2022. Frontiers Cellular Developmental Biology. Generation of a H9 Clonal Cell Line With Inducible Expression of NUP98-KDM5A Fusion Gene in the AAVS1 Safe Harbor Locus.Frontiers. 10, pp.846092. https://doi.org/10.3389/fcell.2022.846092

5 **Artículo científico**. Sanabria de la Torre; Martinez-Heredia L; Gonzalez-Salvatierra S; et al; Garcia-Fontana B; (10/13) Real PJ. 2022. Characterization of genetic variants of uncertain significance for the ALPL gene in patients with adult hypophosphatasia. Frontiers in Endocrinology. Nature Publishing Group. 9-1, pp.9569. https://doi.org/10.3389/fendo.2022.863940

6 **Artículo científico**. Rodriguez-Martinez A; Simon-Saez I; Perales S; et al; Serrano MJ; (13/15) Real PJ. 2022. Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior. Theranostics. Ivyspring. 12-5, pp.2150-2161. https://doi.org/10.7150/thno.64252

7 **Artículo científico**. Yan Q; Wulfridge P; Doherty J; Fernandez-Luna JL; (5/7) Real PJ; Tang HY; Sarma K. 2022. Proximity labeling identifies a repertoire of site-specific R-loop modulators. Nature Communications. Nature Publisher Group. 13-1, pp.53. https://doi.org/10.1038/s41467-021-27722-6

8 **Artículo científico**. Cortijo-Gutiérrez M; Sánchez-Hernández S; Tristán-Manzano M; et al; Benabdellah K; (6/10) Real PJ. 2021. Improved Functionality of Integration-Deficient Lentiviral Vectors (IDLVs) by the Inclusion of IS2 Protein Docks.Pharmaceutics. 13-8, pp.1217. https://doi.org/10.3390/pharmaceutics13081217

9 **Artículo científico**. Simon I; Perales S; Casado-Medina L; et al; (12/12) Real PJ (AC). 2021. Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation. Cancers. MDPI. 13-6, pp.1483. https://doi.org/10.3390/cancers13061483

10 **Artículo científico**. Lamolda M; Montes R; Simon I; et al; (15/15) Real PJ (AC). 2019. GENYOi005-A: an induced pluripotent stem cells (iPSCs) line generated from a patient with Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) carrying a p.Thr196Ala variant. Stem Cell Research. https://doi.org/10.1016/j.scr.2019.101603

11 **Artículo científico**. Garcia-Fontana C; Villa-Suarez JM; Andujar-Vera F; et al; Muñoz-Torres M; (6/10) Real PJ. 2019. Epidemiological, Clinical and genetic study of Hypophosphatasia in a Spanish population: Identification of 2 novel mutations in the ALPL gene. Scientific Reports. Nature Publishing Group. 9-1, pp.9569. https://doi.org/10.1038/s41598-019-46004-2

12 **Artículo científico**. Montes R; Mollinedo P; Perales S; Gonzalez-Lamuño D; Ramos-Mejia V; Fernandez-Luna JL; (7/7) Real PJ (AC). 2019. GENYOi004-A: An induced pluripotent stem cells (iPSCs) line generated from a patient with autism-related ADNP syndrome carrying a pTyr719* mutation.Stem Cell Research. Elsevier. https://doi.org/10.1016/j.scr.2019.101446

13 **Artículo científico**. Bueno C; Calero Nieto FJ; Wang X; et al; Menendez P; (8/17) Real PJ. 2019. Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between AF4-MLL and MLL-AF4 fusions.Haematologica. Ferrata Storti Foundation. https://doi.org/10.3324/haematol.2018.202044

14 **Artículo científico**. Mollinedo P; Kapitanksky O; Gonzalez-Lamuño D; Zaslavsky A; (5/8) Real PJ; Gozes I; Gandarillas A; Fernandez-Luna JL. 2018. Cellular and animal models of skin alterations in the autism-related ADNP syndrome. Scientific Reports. Nature Publishing Group. 9-1, pp.736. https://doi.org/10.1038/s41598-018-36859-2

15 **Artículo científico**. Sanchez-Hernandez S; Gutierrez-Guerrero A; Martin-Guerra R; et al; Benabdellah K; (14/16) Real PJ. 2018. The IS2 Element Improves Transcription Efficiency of Integration-Deficient Lentiviral Vector Episomes.Molecular Therapy Nucleic Acids. Elsevier. 13, pp.16-28.

C.3. Proyectos y Contratos

1 **Proyecto**. PID2023-152099OB-I00, Platelet and tumor derived extracellular vesicles (EVs) as directors of carcinogenesis and metastasis in pancreatic cancer (EVprofiler). Universidad de Granada. Pedro J. Real Luna. (Universidad de Granada: GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government). 01/09/2024-31/08/2028. 187.500 €. Investigador principal.

2 **Proyecto**. Papel de la comunicación mediada por vesículas extracelulares (EVs) entre células tumorales de cáncer de páncreas y plaquetas en la carcinogénesis y metástasis (C-EXP-174-UGR23). Universidad de Granada. Torres Perales C. (Universidad de Granada: GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government). 01/01/2024-31/12/2026. 18.000 €. Miembro de equipo.

3 **Proyecto**. New animal models and therapeutic tools to cure Bernard-Soulier Syndrome. Ministerio de Ciencia e Innovación. Universidades. Pedro J. Real Luna. (Universidad de Granada: GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government). 01/06/2020-29/02/2024. 133.100 €. Investigador principal.

4 **Proyecto**. New animal models and therapeutic tools to cure Bernard-Soulier Syndrome. Ministerio de Ciencia e Innovación. Universidades. Pedro J. Real Luna. (Universidad de Granada: GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government). 01/06/2020-29/02/2024. 133.100 €. Investigador principal.

5 **Proyecto**. RYC-2015-18382. Ministerio de Economía, Industria y Competitividad. Pedro J. Real Luna. (Universidad de Granada: GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government). 01/02/2017-31/01/2022. 308.600 €. Investigador principal.

6 **Proyecto**. NANO3DEVICES: Nanosistema multifuncionalizado con aplicación Teranóstica en Cancer (DTS18/00121). Instituto de Salud Carlos III. (Universidad de Granada: GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government). 01/01/2019-31/12/2020. 78.650 €. Miembro de equipo.

7 **Proyecto**. Desarrollo de estrategias de Terapia Génica-Celular para el tratamiento del Síndrome de Bernard-Soulier. National Health Institute Carlos III. Pedro J. Real Luna. (Universidad de Granada: GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government). 01/01/2017-31/12/2020. 110.715 €. Investigador principal.

8 **Proyecto**. Optimization of in vitro systems for human platelet generation from human pluripotent stem cells: Alternative to the current blood transfusions. (PI-0030-2014). Rosa María Montes Lorenzo. (GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government). 01/08/2015-31/07/2017. 39.100 €. Miembro de equipo.

9 **Proyecto**. Generation of human experimental models of Bernard-Soulier Syndrome using cellular reprogramming. Telemaraton Todos Somos Raros. Pedro J Real. (GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government). 01/03/2015-30/04/2017. 99.015 €. Investigador principal.

10 **Proyecto**. Generation Of Human Experimental Models Of Glanzmann Disease And Bernard-Soulier Syndrome By Cellular Reprogramming. European Commission. Lourdes Lopez Onieva. (GENyO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government). 12/01/2015-11/01/2017. 173.370 €. Coordinador.

11 **Contrato**. Platelets derived Microparticles direct pancreatic carcinogenesis and metastasis and serves as Noninvasive source of early detection and disease progression in pancreatic cancer (PMProfiler) Fundación Roberto Arnal Planelles. Delgado R. 01/07/2021-01/07/2024. 45.000 €.

C.4. Actividades de transferencia y explotación de resultados

1 Pedro José Real Luna; Miguel García Toscano; Pablo Menéndez Buján; Francisco Martín Molina; Óscar Navarro Montero; Verónica Ayllón Cases; Verónica Ramos Mejía; Marién Cobo Pulido; Clara Bueno Uroz; Tamara Romero Escobar. PCT/ES2014/070805. Method to produce megakaryocytes and platelets España. 24/10/2013. FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD.

2 Pablo Menendez Buján; Verónica Ramos Mejía; Clara Bueno Uroz; Pedro J. Real Luna; Gertrudis Ligero; Laura Sánchez; Iván Gutierrez Aranda. PCT/ES2011/070236. Use of a conditioned medium from Human Mesenchymal Stem Cells to differentiate human Pluripotent Stem Cells España. 08/04/2010. FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD.

3 Pedro J. Real Luna; Adolfo A. Ferrando. PCT/US2008/003268. Synergistic Interaction of NOTCH-1 Inhibitors with Glucocorticoids. Estados Unidos de América. 13/03/2007. Columbia University.

C.5. Estancias en centros de I+D+i públicos o privados

Columbia University. Institute for Cancer Genetics. Estados Unidos de América. New York. 01/09/2005-31/03/2009. Posdoctoral.